BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18485500)

  • 1. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.
    Staritz P; Kurz K; Stoll M; Giannitsis E; Katus HA; Ivandic BT
    Int J Cardiol; 2009 Apr; 133(3):341-5. PubMed ID: 18485500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.
    Fontana P; Dupont A; Gandrille S; Bachelot-Loza C; Reny JL; Aiach M; Gaussem P
    Circulation; 2003 Aug; 108(8):989-95. PubMed ID: 12912815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
    Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
    Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
    Rudez G; Bouman HJ; van Werkum JW; Leebeek FW; Kruit A; Ruven HJ; ten Berg JM; de Maat MP; Hackeng CM
    Circ Cardiovasc Genet; 2009 Oct; 2(5):515-21. PubMed ID: 20031628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.
    Lev EI; Patel RT; Guthikonda S; Lopez D; Bray PF; Kleiman NS
    Thromb Res; 2007; 119(3):355-60. PubMed ID: 16581111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
    Smith SM; Judge HM; Peters G; Armstrong M; Fontana P; Gaussem P; Daly ME; Storey RF
    Platelets; 2006 Jun; 17(4):250-8. PubMed ID: 16769602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
    Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
    Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
    von Beckerath N; von Beckerath O; Koch W; Eichinger M; Schömig A; Kastrati A
    Blood Coagul Fibrinolysis; 2005 Apr; 16(3):199-204. PubMed ID: 15795539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
    Gurbel PA; Bliden KP; Etherington A; Tantry US
    Thromb Res; 2007; 121(1):107-15. PubMed ID: 17400283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic variants of platelet ADP receptor P2Y12 associated with changed platelet functional activity and development of cardiovascular diseases].
    Sirotkina OV; Zabotina AM; Berkovich OA; Bazhenova EA; Vavilova TV; Shvartsman AL
    Genetika; 2009 Feb; 45(2):247-53. PubMed ID: 19334620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
    Gurbel PA; Bliden KP; Butler K; Antonino MJ; Wei C; Teng R; Rasmussen L; Storey RF; Nielsen T; Eikelboom JW; Sabe-Affaki G; Husted S; Kereiakes DJ; Henderson D; Patel DV; Tantry US
    Circulation; 2010 Mar; 121(10):1188-99. PubMed ID: 20194878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
    Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
    Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.